1. This approval is granted for the scientific and ethical soundness of the study. The PI shall be responsible to seek all other clearances/approvals required by law/policy including permission from the study sites before conducting the study. 2. Report serious adverse events to REBH within 10 working days after the incident and unexpected events should be included in the continuing review report or the final report. 3. Any changes to the proposal or to the attachments (informed consent and research tools such as forms) should be approved by REBH before implementation. 4. Final report of the study should be submitted to REBH at the end of the study for protocol file closure. 5. This approval is valid through 11/04/2018. If the study has to continue beyond the approved period the PI has to apply for the continuing review two months before the validity of the approval expires.
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